Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Osteoporosis Reports
Published in: Current Osteoporosis Reports 3/2011

01-09-2011

Osteoporosis: A Paradox in Ankylosing Spondylitis

Authors: Shea Carter, Rik J. Lories

Published in: Current Osteoporosis Reports | Issue 3/2011

Login to get access

Abstract

Ankylosing spondylitis is a chronic and severe inflammatory disease of the axial skeleton and the joints. Inflammation is associated with trabecular bone loss leading to osteoporosis but also with corcal new bone formation leading to progressive ankylosis of the spine and sacroiliac joints. This results in an apparent paradox of bone formation and loss taking place at sites closesly located to each other. Osteoporosis can be explained by the impact of inflammation of the bone remodeling cycle. In contrast, new bone formation has been linked to aberrant acvaon of bone morphogenec protein and Wnt signaling. In this commentary, we review recent data on this bone paradox and highlight recent advances including the effect of current drug therapies and the idenfication of new therapeutic targets.
Literature
1.
Appel H et al. Immunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitis. Arthritis Rheum. 2006;54(9):2845–51.PubMedCrossRef
2.
Schett G. Structural bone changes in spondyloarthritis: mechanisms, clinical impact and therapeutic considerations. Am J Med Sci. 2011;341(4):269–71.PubMedCrossRef
3.
4.
El Maghraoui A et al. Osteoporosis, body composition, and bone turnover in ankylosing spondylitis. J Rheumatol. 1999;26(10):2205–9.PubMed
5.
Hanson CA, Shagrin JW, Duncan H. Vertebral osteoporosis in ankylosing spondylitis. Clin Orthop Relat Res. 1971;74:59–64.PubMedCrossRef
6.
7.
Maillefert JF et al. Changes in bone density in patients with ankylosing spondylitis: a two-year follow-up study. Osteoporos Int. 2001;12(7):605–9.PubMedCrossRef
8.
Karberg K et al. Bone loss is detected more frequently in patients with ankylosing spondylitis with syndesmophytes. J Rheumatol. 2005;32(7):1290–8.PubMed
9.
10.
Will R et al. Osteoporosis in early ankylosing spondylitis: a primary pathological event? Lancet. 1989;2(8678–8679):1483–5.PubMedCrossRef
11.
Franck H, Meurer T, Hofbauer LC. Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitis. J Rheumatol. 2004;31(11):2236–41.PubMed
12.
Ghozlani I et al. Prevalence and risk factors of osteoporosis and vertebral fractures in patients with ankylosing spondylitis. Bone. 2009;44(5):772–6.PubMedCrossRef
13.
Dasgupta B et al. Serial estimation of interleukin 6 as a measure of systemic disease in rheumatoid arthritis. J Rheumatol. 1992;19(1):22–5.PubMed
14.
Roche NE et al. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum. 1993;36(9):1286–94.PubMedCrossRef
15.
Gratacos J et al. Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol. 1994;33(10):927–31.PubMedCrossRef
16.
Melis L et al. Systemic levels of IL-23 are strongly associated with disease activity in rheumatoid arthritis but not spondyloarthritis. Ann Rheum Dis. 2010;69(3):618–23.PubMedCrossRef
17.
Lubberts E et al. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance. J Immunol. 2003;170(5):2655–62.PubMed
18.
Jovanovic DV et al. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J Immunol. 1998;160(7):3513–21.PubMed
19.
Kim HR, Lee SH, Kim HY. Elevated serum levels of soluble receptor activator of nuclear factors-kappaB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS). Rheumatology (Oxford). 2006;45(10):1197–200.CrossRef
20.
Vis M et al. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65(11):1495–9.PubMedCrossRef
21.
Appel H et al. Immunohistochemical analysis of osteoblasts in zygapophyseal joints of patients with ankylosing spondylitis reveal repair mechanisms similar to osteoarthritis. J Rheumatol. 2010;37(4):823–8.PubMedCrossRef
22.
Lories RJ, Derese I, Luyten FP. Inhibition of osteoclasts does not prevent joint ankylosis in a mouse model of spondyloarthritis. Rheumatology (Oxford). 2008;47(5):605–8.CrossRef
23.
Obermayer-Pietsch BM et al. Vitamin D receptor initiation codon polymorphism, bone density and inflammatory activity of patients with ankylosing spondylitis. Osteoporos Int. 2003;14(12):995–1000.PubMedCrossRef
24.
De Keyser F et al. Gut inflammation and spondyloarthropathies. Curr Rheumatol Rep. 2002;4(6):525–32.PubMedCrossRef
25.
Uderhardt S et al. Blockade of Dickkopf (DKK)-1 induces fusion of sacroiliac joints. Ann Rheum Dis. 2010;69(3):592–7.PubMedCrossRef
26.
Visvanathan S et al. Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68(2):175–82.PubMedCrossRef
27.
Toussirot E, Wendling D. Anti-inflammatory treatment with bisphosphonates in ankylosing spondylitis. Curr Opin Rheumatol. 2007;19(4):340–5.PubMedCrossRef
Metadata
Title
Osteoporosis: A Paradox in Ankylosing Spondylitis
Authors
Shea Carter
Rik J. Lories
Publication date
01-09-2011
Publisher
Current Science Inc.
Published in
Current Osteoporosis Reports / Issue 3/2011
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI
https://doi.org/10.1007/s11914-011-0058-z

Other articles of this Issue 3/2011

Current Osteoporosis Reports 3/2011 Go to the issue

ReviewPaper

Minor, Major, Low-Trauma, and High-Trauma Fractures: What Are the Subsequent Fracture Risks and How Do They Vary?

ReviewPaper

Diagnostic Thresholds in Osteoporosis: How Are They Used in Clinical Trials?

ReviewPaper

Choosing a Treatment for Patients at the Time a Fracture is Presented

ReviewPaper

Effects of Anti-osteoporosis Medications on Fracture Healing

Clinical Trial Report

Is Two Better Than One? Combining Antiresorptive and Anabolic Osteoporosis Medications

ReviewPaper

The Role of Falls in Fracture Prediction